Fulgent Genetics (FRA:7F0) Change In Receivables : €-5.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Fulgent Genetics Change In Receivables?

Fulgent Genetics's change in receivables for the quarter that ended in Mar. 2024 was €1.4 Mil. It means Fulgent Genetics's Accounts Receivable declined by €1.4 Mil from Dec. 2023 to Mar. 2024 .

Fulgent Genetics's change in receivables for the fiscal year that ended in Dec. 2023 was €2.2 Mil. It means Fulgent Genetics's Accounts Receivable declined by €2.2 Mil from Dec. 2022 to Dec. 2023 .

Fulgent Genetics's Accounts Receivable for the quarter that ended in Mar. 2024 was €47.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Fulgent Genetics's Days Sales Outstanding for the three months ended in Mar. 2024 was 73.67.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Fulgent Genetics's liquidation value for the three months ended in Mar. 2024 was €225.2 Mil.

Fulgent Genetics Change In Receivables Historical Data

The historical data trend for Fulgent Genetics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Change In Receivables Chart

Fulgent Genetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.76

-146.71

37.44

64.79

2.19

Fulgent Genetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															8.72	9.53	-11.30	-4.78	1.37

Fulgent Genetics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.2 Mil.

Fulgent Genetics (FRA:7F0) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Fulgent Genetics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	47.895	/	59.326	*	91
=	73.67

2. In Ben Graham's calculation of liquidation value, Fulgent Genetics's accounts receivable are only considered to be worth 75% of book value:

Fulgent Genetics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	281.239	-	94.98	+	0.75 * 47.895	+	0.5 * 6.006
=	225.2

Fulgent Genetics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics (FRA:7F0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (FRA:7F0) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

FLGT:USA 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Fulgent Genetics (FRA:7F0) Headlines

No Headlines